



A study of Intratympanic Dexamethasone Injection in Meniere's disease (Continuation study)

Thesis

Submitted for partial fulfillment of the Master Degree of Audiology

By

Sameh Mumdouh Abdel Raouf

(M.B., B.Ch)

Under Supervision of

Prof. Dr. Adel Abd El Maksoud Nassar

Head of Audiology Dept., ENT Dept. – Audiology Unit

Faculty of Medicine – Ain Shams University

Dr. Ahmed Ehab Fahim Chedid

Consultant of Audiology

Military Medical Academy

Dr. Rasha Hamdi El-Kabarity

Assistant professor of Audiology, ENT Dept. – Audiology unit

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2017



سورة البقرة الآية: ٣٢



First and above all thanks to **ALLAH**, the most merciful and who is behind all success

Prof. Dr. Adel Abd Elmaksoud Nassar, Professor of Audiology, Faculty of Medicine, Ain Shams University, for his kind supervision, helpful advice and giving much of his precious time and constant support throughout the conduction of this work.

I wish to thank Dr., Rasha Hamdi El-Kabarity

Assistant Professor of Audiology, Faculty of Medicine, Ain Shams University, for her generous assistance, kind cooperation and valuable advice throughout this work.

I am most grateful to Dr., Ahmed Ehab Fahim Chedid

Consultant of Audiology, Military Medical Academy, for his continuous efforts, great help, and advices to make this work at its best.

My deepest thanks for my professors and colleagues of Audiology unit, Ain Shams University & Military Medical Academy for their continuous support.

I would like to thank all patients who participated in this work and last but not the least I would like to thank my family for their sympathy and endless support

Contents

List of Contents

Page

•	Introduction and Rationale	1
•	Aim of the work	6
•	Review of literature	7
	Chapter 1: Meniere's disease:	
	Historical background	7
	Epidemiology of Meniere's disease	9
	Aetiology	12
	Pathogenesis	16
	Clinical picture	25
	Diagnosis of Meniere's disease	35
	Differential diagnosis	42
	Prognosis of Meniere's disease	42
	Chapter 2: Management of Meniere's disease:	
	■ Diet	43
	Medications	44
	Noninvasive procedures	46
	Surgery	46
	Intratympanic Gentamycin	47
	Intratympanic Steroids	47
•	Materials and methods	50
•	Results	57
•	Discussion	. 105
•	Conclusion	. 120
•	Recommendations	. 121
•	Summary	. 122
•	References	
•	Abbreviations	
•	Arabic summary	
_	11 UNIC SUIIIIIIII y	•••

List of Tables

No	Title	Page
1	Diagnostic criteria of Meniere's disease	33
2	The point system of the Gibson score	34
3	Stages of Meniere's disease	36
4	Mean (X), Standard deviation (SD), range and T- test for the age in years in the study subgroups	57
5	Gender distribution in the study subgroups	58
6	Mean (X), Standard deviation (SD), range and T- test for the duration of the disease (in months) in the study subgroups.	60
7	Prognosis of patients of both study subgroups as regards pure tone average (PTA) and word discrimination score (WDS) after FU1 compaired to results in the previous study	61
8	Prognosis of patients of both study subgroups as regards pure tone average (PTA) and word discrimination score (WDS) after FU2 compaired to results in the previous study	61
9	Prognosis of patients of both study subgroups as regards pure tone average (PTA) and word discrimination score (WDS) between FU1 and FU2	62
10	Mean (X), Standard deviation (SD) and T-test of pure tone average, Speech Reception Thresholds (SRT) in dBHL and Word Discrimination Scores (WDS %) for subgroup A after FU1 & FU2.	65

No	Title	Page
11	Mean (X), Standard deviation (SD) and T-test of pure tone average, Speech Reception Thresholds in dBHL and Word Discrimination scores (WDS %) for subgroup B after FU1 & FU2.	67
12	Mean (X), Standard deviation (SD) and T-test for the difference in the basic audiological test results for both study subgroups between the baseline and FU1	68
13	Mean (X), Standard deviation (SD) and T-test for the difference in the basic audiological test results for both study subgroups between the baseline and FU2	69
14	Mean (X), Standard deviation (SD) and T-test for the difference in the basic audiological test results for both study subgroups between FU1 and FU2	70
15	Audiometric configuration in the both study subgroups after FU1 & FU2.	73
16	Chi-Square test and P value of patients presented with spontaneous, post head shaking and positional nystagmus in subgroup A after FU1 and FU2.	74
17	Chi-Square test and P value of patients presented with spontaneous, post head shaking and positional nystagmus in subgroup B after FU1 and FU2.	75
18	Chi-Square and P value between the difference in the VNG subtests results for both study	75

No	Title	Page
	subgroups between baseline and FU1.	
19	Chi-Square and P value between the difference in the VNG subtests results for both studysubgroups between baseline and FU2	76
20	Chi-Square and P value between the difference in the VNG subtests results for both study subgroups between FU1 and FU2.	76
21	Mean, SD , and ANOVA test for the latency of P13 in both study subgroups after FU1 and FU2	77
22	Mean, SD , and ANOVA test for the latency of P13 in both study subgroups after FU1 and FU2	78
23	Mean (X), Standard deviation (SD) and T-test for the difference in the latency of P13 and N23 of both study subgroups between baseline and FU1	79
24	Mean (X), Standard deviation (SD) and T-test for the difference in the latency of P13 and N23 of both study subgroups between baseline and FU2	79
25	Mean (X), Standard deviation (SD) and T-test for the difference in the latency of P13 and N23 of both study subgroups between FU1 and FU2	80
26	Mean, SD, ANOVA test and P value for the amplitude of asymmetry ratio in both study subgroups	80

No	Title	Page
27	Mean (X), Standard deviation (SD) and T-test for the difference in the amplitude of asymmetry ratio of both study subgroups between baseline and FU1	81
28	Mean (X), Standard deviation (SD) and T-test for the difference in the amplitude of asymmetry ratio of both study subgroups between baseline and FU2	82
29	Prognosis of patients of both study subgroups as regards the Dizziness Handicap Inventory scale as regarding the basal data and (FU1).	82
30.A	Prognosis of patients of both study subgroups as regards the Dizziness Handicap Inventory scale in the baseline and first follow up.	83
30.B	Prognosis of patients of both study subgroups as regards the Dizziness Handicap Inventory scale after the first follow up of our study (FU1) compared to the previous study	83
31	Prognosis of patients of both study subgroups as regards the Dizziness Handicap Inventory scale as regarding (FU2) compared to the previous study	84
32	Mean (X), Standard deviation (SD) and ANOVA- test for Dizziness Handicap Inventory scale of subgroup A	85
33	Mean (X), Standard deviation (SD) and ANOVA- test for the Dizziness Handicap Inventory scale of subgroup B	86

No	Title	Page
34	Mean (X), Standard deviation (SD) and T-test for the difference in the Dizziness Handicap Inventory scale of both study subgroups between the baseline and FU1.	87
35	Mean (X), Standard deviation (SD) and T-test for the difference in the Dizziness Handicap Inventory scale of both study subgroups between the baseline and FU2	87
36	Mean (X), Standard deviation (SD) and T-test for the difference in the Dizziness Handicap Inventory scale of both study subgroups between the FU1 and FU2	88
37	Number and percentage of patients who had improvement in subjective hearing loss, tinnitus, vertigo characteristics and aural fullness in both study subgroups after FU1 and FU2	89
38.A	Prognosis of patients of both study subgroups as regards improving in subjective hearing loss, tinnitus and vertigo characteristics regarding the previous study	89
38.B	Prognosis of patients of both study subgroups as regards improving in subjective hearing loss, tinnitus and vertigo characteristics regarding FU1 in comparison with the previous study	90
39	Prognosis of patients of both study subgroups as regards improving in subjective hearing loss, tinnitus and vertigo characteristics regarding FU2 in comaparison with the previous study	91

No	Title	Page
40	Mean (X), Standard deviation (SD) and P value for subjective hearing loss, tinnitus severity and vertigo characteristics in subgroup A after FU1 and FU2	91
41	Mean (X), Standard deviation (SD) and T- test for tinnitus and vertigo characteristics in subgroup B.	94
42	Chi-Square and P value of patients in both study subgroups who had vertigo associated symptoms after FU1 and FU2.	96
43	Mean (X), Standard deviation (SD) and T-test for the difference in the subjective hearing loss, tinnitus and vertigo characteristics of both study subgroups between the baseline and FU1	96
44	Mean (X), Standard deviation (SD) and T-test for the difference in the subjective hearing loss, tinnitus and vertigo characteristics of both study subgroups between the baseline and FU2	98
45	Mean (X), Standard deviation (SD) and T-test for the difference in the subjective hearing loss, tinnitus and vertigo characteristics of both study subgroups between FU1 and FU2	99
46	Nunber and Percentage of patients with aural fullness in both study subgroups after FU1 & FU2	99

No	Title	Page
47	Chi-Square test and P value for the difference in the percentage of the patients with aural fullness among both study subgroups between baseline and FU1.	100
48	Chi-Square test and P value for the difference in the percentage of the patients with aural fullness among both study subgroups between baseline and FU2	101
49	Chi-Square test and P value for the difference in the percentage of the patients with aural fullness among both study subgroups between FU1 and FU2	102
50	Chi-Square test and P value for the difference in the percentage of the stability of cases in all items of the numerical data.	103

No	Title	Page
1	(1a): Normal membranous labyrinth (2b): Dilated membranous labyrinth in Meniere's disease (Hydrops)	19
2	The link between apoptosis of spiral ganglion neurons and endolymphatic hydrops	22
3	Light microscopy photomicrograph of the superior crista and utricular macula from patients with Meniere's disease	24
4	Mean of age both subgroups	58
5	Mean of gender in both subgroups	59
6	Pure tone threshold results of the subgroup A after FU1&FU2	63
7	Mean of SRT (dBHL) and WDS (%) results of the subgroup A after FU1& FU2	64
8	Mean of pure tone threshold results of the subgroup B after FU1 & FU2.	66
9	Mean of SRT (dBHL) and WDS (%) results of the subgroup B after FU1&FU2	67
10	Audiometric configuration in the subgroup A after FU1&FU2	71
11	Audiometric configuration in the subgroup B after FU1&FU2.	71
12	Percentage of patients with spontaneous, post head shaking and positional nystagmus in subgroup A after FU1 and FU2	74

No	Title	Page
13	Percentage of patients with spontaneous, post head shaking and positional nystagmus in subgroup B	75
	after FU1 and FU2	
	Mean of the latency of P 13 and N 23 in both study	
14	subgroups Mean, SD and P-value for the amplitude	78
	asymmetry ratio in both study subgroups.	
15	Mean of the asymmetry ratio in both study	81
	subgroups after FU1& FU2	01
16	Mean of the Dizziness Handicap Inventory Scale in	86
	subgroup A after FU1 and FU2	
17	Mean of the Dizziness Handicap Inventory Scale in	88
	subgroup B after FU1 & FU2	
	Mean of the subjective hearing loss ,tinnitus	
18	scores& the results of vertigo characteristics in	93
	subgroup A after FU1 and FU2.	
19	Mean of the subjective hearing loss, tinnitus	
	scores& the results of vertigo characteristics in	94
	subgroup B after FU1 and FU2	
20	Percentage of patients with aural fullness in both	96
	study subgroups after FU1 and FU2.	

